In the meta-analysis of 11 studies with 8,215 cases and 11,402 controls, the pooled OR for the association between ERCC1 rs11615 polymorphism and lung cancer risk was statistically significant (homozygous: CC versus TT, OR = 1.24, 95% CI: 1.04–1.48, P = 0.02) with moderate among-study heterogeneity (I2 = 22.8%, P = 0.01) (Figure 2A). Here, ERCC1 is linked to lung cancer.